Critical Path Institute

Critical Path Institute, commonly known as C-Path, is a Tucson, Arizona-based nonprofit organization focused on regulatory science and the improvement of the medical-product development process. It was established in 2005 in response to the U.S. Food and Drug Administration's Critical Path Initiative, which was launched in 2004 to address persistent problems in the development, testing, evaluation, and manufacture of drugs, biologics, and other FDA-regulated products. C-Path was created with support from the FDA, Science Foundation Arizona, and the Tucson community, and operates as an independent, neutral third party rather than as a conventional pharmaceutical company or contract research organization. The institute's central operating model is collaborative consortium building. It convenes scientists and specialists from regulatory agencies, academic institutions, patient organizations, pharmaceutical and biotechnology companies, and research organizations. Through these partnerships, C-Path seeks to reduce the time, cost, and uncertainty associated with drug development while improving the quality of evidence available to regulators and sponsors. Its work is especially concentrated in areas where no single institution can easily assemble sufficiently large datasets, establish common standards, or develop broadly accepted clinical trial tools. A major part of C-Path's approach is the creation and analysis of large, aggregated clinical-trial and disease-progression datasets. These resources can be used to understand how diseases evolve, identify populations suitable for clinical studies, evaluate potential biomarkers, and design more efficient trials. The organization also develops clinical outcome assessments, including patient-reported outcome instruments, and quantitative models intended to improve trial design and regulatory decision-making. When the evidence is sufficiently mature, C-Path-supported tools may be submitted to regulatory qualification programs so they can be used across multiple development programs rather than recreated separately for each product. Its portfolio spans safety science, neurology, rare diseases, tuberculosis, transplantation, kidney disease, neonatal medicine, multiple sclerosis, diabetes, and patient-focused outcome measurement. Programs have supported regulatory-science advances such as the qualification or review of imaging and fluid biomarkers in Alzheimer's disease, a kidney-injury safety biomarker panel, the iBox scoring system for kidney-transplant studies, and disease-specific outcome measures. C-Path also manages data platforms and repositories, including resources for tuberculosis studies and rare-disease research. C-Path's activities are not limited to the United States. It has developed European operations, including a nonprofit foundation headquartered in Amsterdam that was established in 2022. In 2023, its Dublin entity was integrated into the Amsterdam foundation to simplify its European structure and strengthen engagement with European stakeholders. In 2024, the institute launched the Global Impact Conference in Washington, D.C., as a cross-therapeutic forum for regulators, industry, academia, and patient communities. The organization remains active as a convening and evidence-development institution, with Klaus Romero as chief executive officer and Kristen Swingle as president and chief operating officer.

Critical Path Institute emerged from the FDA's Critical Path Initiative, announced in 2004 to improve the scientific and operational foundations of medical-product development. The initiative reflected concerns that scientific advances were not being translated into approved therapies efficiently enough, and that drug-development methods, endpoints, biomarkers, and manufacturing practices often lacked shared standards. C-Path was incorporated in Tucson in 2005 with support from the FDA, Science Foundation Arizona, and local stakeholders. Raymond L. Woosley, a physician and pharmacologist, founded the organization and later became its president emeritus. C-Path was designed to fill a role between government, academia, patient communities, and industry. Its neutrality allows competing companies and public institutions to contribute data and expertise to common projects while leaving product-specific commercial decisions to sponsors. Rather than developing branded medicines, the institute develops public-interest tools for regulatory science: aggregated datasets, disease models, biomarkers, clinical outcome assessments, and analytical methods. These resources are intended to make trials more informative, reduce duplication, and give regulators and sponsors better evidence for decisions. One of its important early areas of work was Alzheimer's disease. C-Path's Critical Path for Alzheimer's Disease program helped assemble evidence around imaging and cerebrospinal-fluid biomarkers, including hippocampal volume and measures associated with amyloid and tau pathology. The European Medicines Agency issued a qualification opinion in 2011 for low hippocampal volume measured by MRI as an enrichment tool in predementia Alzheimer's trials. In 2015, the FDA issued letters of support for MRI hippocampal volume and cerebrospinal-fluid biomarkers as exploratory enrichment tools. These developments illustrated C-Path's broader method: combine data and expert review to establish how a measurement may be used in future studies. The institute subsequently expanded into safety, patient-focused measurement, infectious disease, rare disease, neurology, kidney disease, transplantation, neonatal medicine, and other fields. The Predictive Safety Testing Consortium worked on biomarkers for drug-induced toxicity and contributed to the evidence base for a composite urinary biomarker panel. In 2018, the FDA issued its first qualification of a clinical safety biomarker panel for drug-induced kidney injury in Phase 1 trials. Other programs developed or evaluated trial tools for tuberculosis, polycystic kidney disease, Parkinson's disease, Huntington's disease, Duchenne muscular dystrophy, multiple sclerosis, type 1 diabetes, neonatal therapies, and transplantation. C-Path also created data infrastructure. The TB-PACTS platform curates and standardizes Phase III tuberculosis-trial data, while the Relational Sequencing TB Data Platform links tuberculosis genomic variants with drug-susceptibility and clinical information. The Rare Disease Clinical Outcome Assessment and Data Analytics Platform, established in 2019 with FDA support and co-led with the National Organization for Rare Disorders, provides a centralized environment for patient-level rare-disease data and analytics. In 2022, C-Path convened the rare neurodegenerative disease consortium RND under the public-private partnership contemplated by the U.S. ACT for ALS law, working with FDA and NIH on tools and standards for ALS and related conditions. The organization's international structure developed further in Europe. A European nonprofit foundation headquartered in Amsterdam was established in March 2022 to broaden collaboration with European stakeholders. In July 2023, C-Path integrated its Dublin entity into the Amsterdam foundation. In 2024, it launched the Global Impact Conference in Washington, D.C., creating a recurring forum for discussion of regulatory-science advances across therapeutic areas; a second conference followed in September 2025. C-Path continues to operate as an active nonprofit consortium and data-science organization, led by CEO Klaus Romero and President and Chief Operating Officer Kristen Swingle.

• 2025

  FDA accepts an expanded renal biomarker qualification plan

  [1]Critical Path Instituteen.wikipedia.org

  The FDA accepts a qualification plan for an expanded urine biomarker panel addressing early renal response to drug-induced injury.

• 2024

  Global Impact Conference launches

  [1]Critical Path Instituteen.wikipedia.org

  C-Path launches a Washington, D.C. conference intended to share regulatory-science advances across therapeutic areas.

• 2022

  European foundation and RND consortium expand C-Path's reach

  [1]Critical Path Instituteen.wikipedia.org

  C-Path establishes an Amsterdam-based European foundation and convenes the rare neurodegenerative disease consortium under the U.S. ACT for ALS framework.

• 2022

  EMA issues qualification opinion for the iBox scoring system

  [1]Critical Path Instituteen.wikipedia.org

  The EMA qualifies iBox as a secondary efficacy endpoint for kidney-transplant trials.

• 2019

  Rare-disease data platform is established

  [1]Critical Path Instituteen.wikipedia.org

  C-Path and the National Organization for Rare Disorders establish RDCA-DAP with FDA support.

• 2018

  First FDA qualification of a clinical kidney-safety biomarker panel

  [1]Critical Path Instituteen.wikipedia.org

  A urinary biomarker panel associated with C-Path's predictive safety work is qualified for use in Phase 1 studies of drug-induced kidney injury.

• 2015

  FDA supports Alzheimer's disease biomarker use

  [1]Critical Path Instituteen.wikipedia.org

  The FDA issues letters of support for MRI hippocampal volume and cerebrospinal-fluid amyloid and tau measures as exploratory enrichment biomarkers.

• 2011

  EMA qualifies MRI hippocampal volume as an enrichment tool

  [1]Critical Path Instituteen.wikipedia.org

  The European Medicines Agency issues a qualification opinion for low hippocampal volume measured by MRI in predementia Alzheimer's disease trials.

• 2005

  Critical Path Institute is established

  [1]Critical Path Instituteen.wikipedia.org

  C-Path is created in Tucson as an independent nonprofit with support from the FDA, Science Foundation Arizona, and the local community.

• 2004

  FDA launches the Critical Path Initiative

  [1]Critical Path Instituteen.wikipedia.org

  The FDA begins a program aimed at improving the methods used to develop, evaluate, and manufacture regulated medical products.

A neutral, nonprofit regulatory-science intermediary that converts shared clinical evidence and cross-sector collaboration into standards, biomarkers, outcome measures, data platforms, and trial methods that can support more efficient medical-product development.

• Safety biomarkers

  Predictive Safety Testing Consortium

  A public-private consortium that develops and evaluates biomarkers intended to detect drug-induced toxicity earlier than conventional clinical measures. Its work contributed to the qualification of a composite urinary biomarker panel for kidney injury in Phase 1 trials and to later expansion of the renal biomarker qualification program.

• Clinical outcome assessment

  Patient-Reported Outcome Consortium

  A program that develops, evaluates, and seeks qualification for patient-reported outcome instruments, including questionnaires used to measure symptoms, functioning, and treatment effects in clinical trials.

• Neurodegenerative disease regulatory science

  Critical Path for Alzheimer's Disease

  A consortium focused on improving development of therapies for Alzheimer's disease and related disorders. It has supported work on disease-progression evidence and biomarkers such as MRI hippocampal volume and cerebrospinal-fluid amyloid and tau measures.

• Tuberculosis drug development

  Critical Path to TB Drug Regimens

  A program seeking shorter, safer, and more effective tuberculosis treatment regimens by improving trial methods, sharing evidence, and supporting regulatory-science tools for regimen development.

• Clinical data platform

  TB-PACTS

  A curated platform that aggregates and standardizes Phase III tuberculosis clinical-trial data, enabling comparative analyses and supporting the design and evaluation of new tuberculosis regimens.

• Transplantation regulatory science

  Transplant Therapeutics Consortium

  A consortium working to accelerate medical-product development in transplantation. Its iBox scoring system is intended to provide a secondary efficacy endpoint for kidney-transplant trials and has progressed through European and U.S. qualification processes.

• Rare-disease data platform · 2019

  RDCA-DAP

  A centralized repository and analytics hub for patient-level rare-disease data. Established with FDA support and co-led with the National Organization for Rare Disorders, it supports development of outcome measures, models, and other drug-development tools across conditions.

• Rare-disease regulatory science · 2022

  Rare neurodegenerative disease consortium

  A public-private consortium convened with FDA and NIH under the U.S. ACT for ALS framework. It develops tools and standards intended to accelerate therapies for ALS and related rare neurodegenerative diseases.

• Scientific data infrastructure

  Data Collaboration Center

  A C-Path program that develops data solutions for scientific research, including approaches for organizing, integrating, and analyzing evidence used in regulatory-science projects.

• 2024Global Impact Conference

  United States · International

  C-Path launched a Washington, D.C. conference to bring regulators, life-science companies, academics, and patient organizations together around cross-therapeutic regulatory-science progress.

  Outcome. The event established a recurring forum; a second conference was held in September 2025.

  Source

• 2024

  Launch of the Global Impact ConferenceOther

  Background

  C-Path identified a need for a broad forum covering regulatory-science advances across therapeutic areas.

  Action taken

  It launched the Global Impact Conference in Washington, D.C.

  Aftermath

  The conference continued with a second meeting in September 2025.

  Source

• 2023

  Integration of Dublin operations into the Amsterdam foundationStrategy

  Background

  C-Path reviewed its European operating structure after establishing the Amsterdam-based foundation.

  Action taken

  The Dublin entity was integrated into the Amsterdam foundation.

  Aftermath

  The change was intended to simplify European operations and support engagement with European stakeholders.

  Source

• 2022

  Establishment of a European nonprofit foundationStrategy

  Background

  C-Path sought to broaden collaboration with European regulators, researchers, patient organizations, and industry.

  Action taken

  It established a nonprofit foundation headquartered in Amsterdam.

  Aftermath

  The European structure was later streamlined when C-Path integrated its Dublin entity into the Amsterdam foundation in 2023.

  Source

1. 1Critical Path Instituteen.wikipedia.org
2. 2Critical Path Institute official websitec-path.org